Impact of aortic angle on transcatheter aortic valve implantation outcome with Evolut-R, Portico, and Acurate-NEO.
Acurate-NEO
Evolut-R
Portico
TAVI
aortic angle
Journal
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
ISSN: 1522-726X
Titre abrégé: Catheter Cardiovasc Interv
Pays: United States
ID NLM: 100884139
Informations de publication
Date de publication:
01 01 2021
01 01 2021
Historique:
received:
09
01
2020
revised:
05
04
2020
accepted:
25
04
2020
pubmed:
14
5
2020
medline:
25
9
2021
entrez:
14
5
2020
Statut:
ppublish
Résumé
To investigate paravalvular leak (PVL) and devices success rates according to aortic angle (AA) in patients undergoing transcatheter aortic valve implantation (TAVI) with three new-generation self-expanding devices. The impact of aortic angle (AA) on TAVI device success and PVL rates is controversial. This retrospective study included 392 patients submitted to TAVI for severe aortic stenosis with Portico, Evolut-R and Acurate-NEO, and available AA measurements at computed tomography (CT) angiography. AA was calculated from the implantation projection and was defined as the angle between the plane of aortic annulus and an ideal horizontal plane. Aorta was defined horizontal if AA>57° (75th percentile). In the horizontal group, the rates of moderate/severe PVL was higher in the Evolut-R group (20.8%), which was also characterized by a lower implant compared to that of Acurate-NEO, whereas device success was comparable among the three devices. AA was a significant predictor of moderate/severe PVLs (AUC 0.72, p = .002) only in the Evolut-R population. On multivariate analysis, calcium volume 850HU, bicuspid aortic valve, and implantation depth at the level of left coronary cusp were independent predictors of moderate/severe PVL. On univariate analysis in the horizontal aorta population, implantation depth was confirmed among the most significant predictors of moderate/severe PVL. Despite comparable device success rates, horizontal aorta represented a technical challenge only in the Evolut-R subgroup, which showed higher rates of moderate/severe PVL than Portico and Acurate-NEO, and was associated with a low implant.
Sections du résumé
OBJECTIVES
To investigate paravalvular leak (PVL) and devices success rates according to aortic angle (AA) in patients undergoing transcatheter aortic valve implantation (TAVI) with three new-generation self-expanding devices.
BACKGROUND
The impact of aortic angle (AA) on TAVI device success and PVL rates is controversial.
METHODS
This retrospective study included 392 patients submitted to TAVI for severe aortic stenosis with Portico, Evolut-R and Acurate-NEO, and available AA measurements at computed tomography (CT) angiography. AA was calculated from the implantation projection and was defined as the angle between the plane of aortic annulus and an ideal horizontal plane. Aorta was defined horizontal if AA>57° (75th percentile).
RESULTS
In the horizontal group, the rates of moderate/severe PVL was higher in the Evolut-R group (20.8%), which was also characterized by a lower implant compared to that of Acurate-NEO, whereas device success was comparable among the three devices. AA was a significant predictor of moderate/severe PVLs (AUC 0.72, p = .002) only in the Evolut-R population. On multivariate analysis, calcium volume 850HU, bicuspid aortic valve, and implantation depth at the level of left coronary cusp were independent predictors of moderate/severe PVL. On univariate analysis in the horizontal aorta population, implantation depth was confirmed among the most significant predictors of moderate/severe PVL.
CONCLUSIONS
Despite comparable device success rates, horizontal aorta represented a technical challenge only in the Evolut-R subgroup, which showed higher rates of moderate/severe PVL than Portico and Acurate-NEO, and was associated with a low implant.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
E135-E145Informations de copyright
© 2020 Wiley Periodicals, Inc.
Références
Leon MB, Smith CR, Mack MJ, et al. PARTNER 2 investigators. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med. 2016;374:1609-1620.
Mack MJ, Leon MB, Smith CR, et al. PARTNER 1 trial investigators. 5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomized controlled trial. Lancet. 2015;385:2477-2484.
Al-Lamee R, Godino C, Colombo A. Transcatheter aortic valve implantation: current principles of patient and technique selection and future perspectives. Circ Cardiovasc Interv. 2011;4:387-395.
Gorla R, De Marco F, Morganti S, et al. Transcatheter aortic valve implantation with Portico and Evolut-R in patients with elliptic aortic annulus. Eurointervention. 2020;15(8):e1588-e1591. https://doi.org/10.4244/EIJ-D-19-00115.
Adams DH, Popma JJ, Reardon MJ, et al. U.S. CoreValve clinical investigators. Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med. 2014;370:1790-1798.
Abramowitz Y, Maeno Y, Chakravarty T, et al. Aortic angulation attenuates procedural success following self-expandable but not balloon-expandable TAVR. JACC Cardiovasc Interv. 2016;9:964-972.
D'Ancona G, Kische S, El-Mawardy M, et al. Aortic annulus angulation does not attenuate procedural success of transcatheter aortic valve replacement using a novel self-expanding bioprosthesis. Heart Vessels. 2019;34:1969-1975. https://doi.org/10.1007/s00380-019-01436-8.
Jilaihawi H, Makkar RR, Kashif M, et al. A revised methodology for aortic valvar complex calcium quantification for transcatheter aortic valve implantation. Eur Heart J Cardiovasc Imaging. 2014;15:1324-1332.
Tzikas A, Amrane H, Bedogni F, et al. Transcatheter aortic valve replacement using the portico system: 10 things to remember. J Interv Cardiol. 2016;29:523-529.
Sinning JM, Werner N, Nickenig G, Grube E. Medtronic CoreValve Evolut-R with EnVeo R. Eurointervention. 2013;9(S95):6.
Barbanti M, Todaro D. Midterm outcomes with the self-expanding ACURATE neo aortic bioprosthesis: the “bumblebee paradox” in transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2018;11:1375-1376.
Petronio AS, Sinning JM, Van Mieghem N, et al. Optimal implantation depth and adherence to guidelines on permanent pacing to improve results of transcatheter aortic valve replacement with the Medtronic CoreValve system: the CoreValve prospective international post-marker ADVANCE-II study. JACC Cardiovasc Interv. 2015;8:837-846.
Kappetein AP, Head SJ, Généreux P, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the valve academic research Consortium-2 consensus document. J Am Coll Cardiol. 2012;60:1438-1454.
Sherif MA, Abdel-Wahab M, Stoecker B, et al. Anatomic and procedural predictors of paravalvular aortic regurgitation after implantation of the Medtronic CoreValve bioprosthesis. J Am Coll Cardiol. 2010;56:1623-1629.
Di Stefano D, Colombo A, Mangieri A, et al. Impact of horizontal aorta on procedural and clinical outcomes in second-generation transcatheter aortic valve implantation. Eurointervention. 2019;15:e749-e756. https://doi.org/10.4244/EIJ-D-19-00455.
Toutouzas K, Benetos G, Voudris V, et al. Pre-dilatation versus no pre-dilatation for implantation of a self-expanding valve in all comers undergoing TAVR: the DIRECT trial. JACC Cardiovasc Interv. 2019;12:767-777.